gemcitabine + cisplatin induction chemotherapy plus concurrent chemoradiotherapy

Gemcitabine + cisplatin induction chemotherapy plus concurrent chemoradiotherapy (CCRT + GP) is a combination treatment regimen primarily used for locoregionally advanced nasopharyngeal carcinoma (NPC). The regimen consists of an initial phase of induction chemotherapy with gemcitabine and cisplatin (GP), followed by concurrent administration of platinum-based chemotherapy (usually cisplatin) with radiotherapy. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while cisplatin forms DNA crosslinks leading to apoptosis. This approach aims to improve survival outcomes by eradicating micrometastases early and enhancing the efficacy of subsequent radiochemotherapy. Clinical trials have shown that adding GP-based induction chemotherapy to CCRT significantly improves failure-free survival, overall survival, and distant metastasis-free survival compared to CCRT alone in patients with advanced NPC[1][2][4][5]. The regimen is associated with increased rates of hematologic toxicities such as neutropenia and thrombocytopenia but remains generally well tolerated[1][4][5].

Other names

CCRT + GPGP + CCRTgemcitabine and cisplatin induction chemotherapy plus concurrent chemoradiotherapy